Document text
Principal Investigator: Timothy S McConnell
Organization: ATLASXOMICS INC.
Fiscal Year: 2024
Award: $399,929
Funding agency: National Human Genome Research Institute
In this Phase I SBIR study, AtlasXomics will develop a next-generation spatial deposition process to expand
tissue type compatibility, minimize end-user processing, and allow adaptation into larger automation
workflows. Epigenetics is critical in regulating gene expression in healthy and diseased tissue cells.
Incorporating genome-wide epigenetics illuminates research into cancer, neurodegenerative diseases, and
systems biology. Systematic epigenomic tissue analysis will allow researchers to bring to bear the power of
spatial multi-modal omics to a broad range of disease research. An epigenomics tool accessible to bench
scientists remains an unmet need. AtlasXomics launched the first genome-wide spatial epigenomics tool,
spatial-ATAC-seq, built on our Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq)
platform. An automatable version of our DBiT-seq device will provide this missing puzzle piece but requires
greater flexibility, throughput, and ease of use. Early adopters applied our assays to human melanoma, brain
cancer, and neurodegenerative diseases. Based on positive early adopter feedback, we have set key
objectives for a next-generation product with 1) improved ease of use, 2) greater flexibility for application to a
wider array of tissue types, 3) larger field of view (FOV) approaching single-cell resolution, and 4) at a lower
cost for large-scale epigenomics studies. To meet this critical need, AtlasXomics will develop a process
substantially reducing the end user’s process steps and pain points, delivering a widely accessible spatial
platform. We have developed a prototype FlowGel process using the current commercial consumable (25um
resolution, 2.5x2.5mm FOV) to map chromatin accessibility in fresh-frozen mouse brains. Once finalized, the
process and consumables will be transferable to all other AtlasXomics applications currently in development.
The positive results from this proof-of-principal study set the groundwork for AtlasXomics to deliver a more
robust, user-friendly, low-cost spatial epigenomic product. Aim 1: Prove the FlowGel at a larger FOV
dramatically minimizes researchers’ bench time, reducing human error and improving quality. Aim 2: Make the
FlowGel chip and hardware and demonstrate their superior performance with various tissue types over our
current commercial technology. Transition to Phase II. We will supply three customers with FlowGel kits and
training to carry out FlowGel-enabled spatial assays and map out product requirements for small labs and
more extensive automated operations.
Terms: <ATAC sequencing><ATAC-seq><ATACseq><Assay><Assay for Transposase-Accessible Chromatin using sequencing><Automation><Bar Codes><Bioassay><Biological Assay><Body Tissues><Brain><Brain Cancer><Brain Nervous System><Cancers><Cell Body><Cells><Chromatin><Custom><Data Analyses><Data Analysis><Degenerative Neurologic Disorders><Deposit><Deposition><Development><Devices><Disease><Disorder><Encephalon><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Failure><Feedback><Freezing><Gel><Gene Expression><Human><Hydrogels><Investigators><Legal patent><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Brain><Malignant neoplasm of brain><Maps><Melanoma><Methods><Mice><Mice Mammals><Microfluidics><Modern Man><Murine><Mus><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Pain><Painful><Patents><Performance><Phase><Process><Production><Property><Protocol><Protocols documentation><Quality Control><Research><Research Personnel><Researchers><Resolution><Running><SBIR><Scientist><Small Business Innovation Research><Small Business Innovation Research Grant><Specificity><Spottings><Structure><Systems Biology><Technology><Testing><Time><Tissue Arrays><Tissue Chip><Tissue Expansion><Tissue Microarray><Tissues><Training><Transcription Initiation Site><Transcription Start Site><Variant><Variation><aged><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><barcode><cost><customs><data interpretation><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><design><designing><developmental><epigenetic biomarker><epigenetic marker><epigenetically><epigenomics><fabrication><field based data><field learning><field study><field test><flexibility><flexible><genome scale><genome-wide><genomewide><high level production><high scale production><high volume manufacturing><high volume production><human error><improved><interest><malignancy><meeting><meetings><multi-modality><multimodality><multiomics><multiple omics><neoplasm/cancer><neurodegenerative illness><next generation><operation><operations><panomics><prototype><resolutions><sequencing platform><success><tool><usability><user-friendly><µfluidic>